Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Low skeletal muscle is associated with toxicity in patients included in phase I trials.

Cousin S, Hollebecque A, Koscielny S, Mir O, Varga A, Baracos VE, Soria JC, Antoun S.

Invest New Drugs. 2014 Apr;32(2):382-7. doi: 10.1007/s10637-013-0053-6. Epub 2013 Dec 17.

PMID:
24343673
2.

Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.

Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, Paci A, Deroussent A, Schlumberger M, Antoun S.

J Clin Endocrinol Metab. 2013 Jun;98(6):2401-8. doi: 10.1210/jc.2013-1115. Epub 2013 Mar 29.

PMID:
23543666
3.

Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.

Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J.

Nutr Cancer. 2014;66(4):583-9. doi: 10.1080/01635581.2014.894103. Epub 2014 Apr 7.

PMID:
24707897
4.

Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer.

Antoun S, Borget I, Lanoy E.

Curr Opin Support Palliat Care. 2013 Dec;7(4):383-9. doi: 10.1097/SPC.0000000000000011.

PMID:
24189893
5.

Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.

Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S.

Am J Clin Nutr. 2010 Apr;91(4):1133S-1137S. doi: 10.3945/ajcn.2010.28608C. Epub 2010 Feb 17.

6.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.

Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28.

PMID:
24880774
7.

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB.

Clin Cancer Res. 2009 Apr 15;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242. Epub 2009 Apr 7.

8.

Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.

Cushen SJ, Power DG, Teo MY, MacEneaney P, Maher MM, McDermott R, O'Sullivan K, Ryan AM.

Am J Clin Oncol. 2017 Feb;40(1):47-52. doi: 10.1097/COC.0000000000000061.

PMID:
24685884
9.

Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.

Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.

Strahlenther Onkol. 2003 Oct;179(10):673-81.

PMID:
14566475
10.

Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.

Cancer Chemother Pharmacol. 2012 Nov;70(5):755-61. doi: 10.1007/s00280-012-1919-6. Epub 2012 Aug 9.

PMID:
22875080
11.

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy.

LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD.

Cancer Chemother Pharmacol. 2010 Mar;65(4):775-80. doi: 10.1007/s00280-009-1084-8. Epub 2009 Aug 1.

12.

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.

Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, Fizazi K, di Palma M, Baracos VE, Escudier B.

Cancer. 2013 Sep 15;119(18):3377-84. doi: 10.1002/cncr.28218. Epub 2013 Jun 25.

14.

Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma.

Guo L, Lin HX, Xu M, Chen QY, Wang CT, Huang PY.

Chin J Cancer. 2010 Feb;29(2):136-9.

15.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
16.

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.

Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR.

Anticancer Drugs. 2005 Oct;16(9):997-1002.

PMID:
16162976
17.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM)..

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
18.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

19.

[Impact of cancer muscle mass loss on anticancer treatment toxicities].

Chemama S, Raynard B, Antoun S.

Bull Cancer. 2016 Sep;103(9):786-93. doi: 10.1016/j.bulcan.2016.04.002. Epub 2016 May 17. Review. French.

PMID:
27206822
20.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.

Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. Epub 2006 Nov 30.

PMID:
17136542

Supplemental Content

Support Center